Press Release: Mergers: Commission approves acquisition of GSK’s oncology business by Novartis, subject to conditions

The European Commission found the proposed acquisition of the oncology business of GlaxoSmithKline plc. ("GSK") of the United Kingdom by Novartis of Switzerland to be in line with the EU Merger Regulation.
The transaction was part of a 3-part inter-conditional deal: in a separately notified case (M.7276), GSK had announced its intention to acquire Novartis' global human vaccines business except for the influenza vaccines business, and to combine GSK's and Novartis' global consumer health business in a new venture, over which GSK would be exercising sole control.

ESO: Background information: Mergers: Commission approves both GSK's acquisition of Novartis' vaccines business and a consumer healthcare joint venture between GSK and Novartis, subject to conditions http://www.europeansources.info/record/press-release-mergers-commission-approves-both-gsks-acquisition-of-novartis-vaccines-business-and-a-consumer-healthcare-joint-venture-between-gsk-and-novartis-subject-to-conditions/

---